Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes

This study has been terminated.
(Recruitment goals could not be met.)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00177424
First received: September 12, 2005
Last updated: June 26, 2014
Last verified: February 2009

September 12, 2005
June 26, 2014
July 2004
October 2007   (final data collection date for primary outcome measure)
The primary outcome will be the incidence of Major Depression post-stroke. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
The primary outcome will be the incidence of Major Depression post-stroke.
Complete list of historical versions of study NCT00177424 on ClinicalTrials.gov Archive Site
Additional outcomes will include the severity of depressive symptoms post-stroke as measured by the Hamilton Depression Rating Scale, and the level of disability experienced by the two treatment groups, as measured by the Functional Independence Measure. [ Time Frame: 12 months ] [ Designated as safety issue: No ]
Additional outcomes will include the severity of depressive symptoms post-stroke as measured by the Hamilton Depression Rating Scale, and the level of disability experienced by the two treatment groups, as measured by the Functional Independence Measure.
Not Provided
Not Provided
 
Sertraline for Preventing Post-stroke Depression and Improving Rehabilitation Outcomes
Intervention to Prevent Post-Stroke Major Depression.

This study will determine the effectiveness of sertraline administration after a stroke in preventing the onset of post-stroke depression.

Persons who suffer from a stroke are at high risk for developing post-stroke major depression (PSMD), an illness that has a negative impact on post-stroke physical rehabilitation and is associated with increased morbidity and mortality. Unfortunately, early detection and successful treatment of post-stroke major depression improves, but does not normalize, stroke rehabilitation outcomes compared to stroke survivors who never developed post-stroke depression. Therefore, preventing the onset of PSMD and its associated disability is an attractive possibility. This study is a placebo controlled, 10-month double-blind trial of sertraline in the prevention of PSMD in stroke survivors, with a 2-month naturalistic continuation phase. The primary outcome will be the incidence of Major Depression post-stroke. Additional outcomes will include the severity of depressive symptoms post-stroke and the level of disability experienced by the two treatment groups. An exploratory analysis will also be conducted to elucidate participant characteristics that may be moderators of the participants' response to the preventive intervention, thereby refining the profile of disabled stroke survivors most likely to benefit from the preventive intervention.

For information on a related study, please follow this link:

http://clinicaltrials.gov/show/NCT00781326

Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Cerebrovascular Accident
  • Depression
  • Drug: sertraline
    Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
  • Drug: Placebo
    matching placebo tablets
  • Active Comparator: 1
    Sertraline
    Intervention: Drug: sertraline
  • Placebo Comparator: 2
    matching placebo
    Intervention: Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
154
October 2007
October 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Ischemic stroke within 3 months of study entry
  • Admitted to a UPMC hospital for acute inpatient treatment or rehabilitation of stroke
  • Speaks English
  • Females willing to use an effective form of birth control throughout the study

Exclusion Criteria:

  • Meets DSM-IV-TR criteria for a major depressive episode
  • History of any bipolar disorder
  • Psychotic or history of a psychotic disorder
  • Meets DMS-IV TR criteria for alcohol or substance abuse or dependence criteria within 3 months of study entry
  • Current treatment with antidepressant medication for any reason (e.g., anxiety disorder, neuropathic pain)
  • Primary hemorrhagic stroke
  • Language impairment severe enough to prevent valid neuropsychiatric assessment
  • History of another CNS disease other than prior stroke or psychiatric illness (e.g., head trauma, multiple sclerosis, HIV with CNS involvement)
  • Pulse <50 or >100 beats per minute
  • Significant hyponatremia (Na <130meq)
  • Current hypothyroid state
  • Medically unstable including symptoms of delirium (determined by review of the subject's medical status with the treating (clinical) physician; standard blood chemistry lab work will be obtained if not checked within the preceding 30 days)
  • History of sensitivity to sertraline
  • Pregnant or breastfeeding
Both
40 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00177424
K23 MH067710-02, K23MH067710-02, 0310068, DATR AK-TNGP1
Not Provided
University of Pittsburgh
University of Pittsburgh
National Institute of Mental Health (NIMH)
Principal Investigator: Ellen M Whyte, MD University of Pittsburgh
University of Pittsburgh
February 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP